Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease involving the superficial fascia.
No HPO annotations are available for this condition.
Age of onset: at birth, childhood.
MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN) is a classic axonal peripheral sensorimotor neuropathy characterized by earlier and more severe involvement of the lower extremities than the upper extremities, distal upper-extremity involvement as the neuropathy progresses, and more prominent motor deficits than sensory deficits. MFN2-HMSN can be caused by a heterozygous pathogenic variant (autosomal dominant inheritance) or biallelic pathogenic variants (semi-dominant inheritance or autosomal recessive inheritance). The phenotypes associated with the different modes of inheritance do not differ significantly .
Formal diagnostic criteria for MFN2 hereditary motor and sensory neuropathy have not been established.
MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN) should be considered in individuals with the following clinical and neurophysiologic findings. Note: No specific findings distinguish MFN2-HMSN from other inherited hereditary motor and sensory neuropathies.
Clinical findings
No approved treatments are currently available for subcutaneous tissue disorder. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with MFN2 hereditary motor and sensory neuropathy (MFN2-HMSN), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with MFN2 Hereditary Motor and Sensory Neuropathy
Table 4. Recommended Surveillance for Individuals with MFN2 Hereditary Motor and Sensory Neuropathy
System/Concern |
|---|
No clinical trials have been registered for subcutaneous tissue disorder.
240 publications have been identified in PubMed for subcutaneous tissue disorder. Kisho has analyzed 141 by research type. Research spans Review / Meta-Analysis (43%), Basic Science / Preclinical (15%), and Other (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 60 | 43% |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 7:13 PM UTC
European rare disease database
The age at onset and disease progression of MFN2-HMSN vary within and among families; onset ranges from age one year to the sixth decade. Most ind...
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Involvement of the lower extremities earlier and more severely than the upper extremities
Involvement of the distal upper extremities as the neuropathy progresses
Motor deficits more prominent than sensory deficits
Optic atrophy (~7% in the autosomal dominant form, and ~20% in the autosomal recessive form)
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
All hereditary motor and sensory neuropathy (HMSN) forms in which axonal phenotypes have been reported, including PMP22-HMSN, MPZ-HMSN, and GJB1-HMSN (see GJB1 Disorders) need to be considered in the differential diagnosis of MFN2-HMSN. See Charcot-Marie-Tooth Hereditary Neuropathy Overview. MFN2 pathogenic variants are by far the most common cause of autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2). As many as one third of all individuals with CMT2 with a positive family history have a pathogenic variant in MFN2 . Thus, testing of MFN2 is probably the first genetic test to consider in families with an axonal neuropathy demonstrating male-to-male transmission.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Biomarker and diagnostic research for subcutaneous tissue disorder has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
neuropathy | Neurologic exam | To determine extent of weakness atrophy, pes cavus, gait stability, sensory loss EMG w/NCV |
Musculoskeletal | Orthopedics / physical medicine rehab / PT OT eval | To incl assessment of:; Gross motor fine motor skills need for PT (to improve gross motor skills) /or OT (to improve fine motor skills); Feet for evidence of pes cavus, need for AFOs, specialized shoes; Mobility, ADL, need for adaptive devices; Need for handicapped parking |
Optic atrophy | Ophthalmologic exam incl VEP | To incl visual acuity, color vision testing, visual field testing for evidence of central scotomas Genetic |
counseling | By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of MFN2-HMSN to facilitate medical personal decision making Family support resources |
Recommended Surveillance for Individuals with MFN2 Hereditary Motor and Sensory Neuropathy System/Concern | Evaluation | Frequency Neurologic |
Imaging | MRI of legs to assess amount location of fat replacing muscles1 | Specialized centers only, every few yrs |
Foot exam | For pressure sores or poorly fitting footwear | Annually |
Vision | Those w/o visual manifestations | Routine ophthalmologic exam |
Those w/opticatrophy | Assessment of visual acuity, visual fields | Per treating ophthalmologist Assessment of low vision aids |
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Obesity, which makes walking more difficult, should be avoided. Medications that are toxic or potentially toxic to persons with CMT comprise a spectrum of risk ranging from definite high risk to negligible risk. See the Charcot-Marie-Tooth Association website for an up-to-date list.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
View trials for subcutaneous tissue disorder
Evaluation
Frequency |
|---|
Imaging | MRI of legs to assess amount location of fat replacing muscles1 | Specialized centers only, every few yrs |
Foot exam | For pressure sores or poorly fitting footwear | Annually |
Vision | Those w/o visual manifestations | Routine ophthalmologic exam |
Those w/opticatrophy | Assessment of visual acuity, visual fields | Per treating ophthalmologist Assessment of low vision aids |
Source: GeneReviews — "MFN2 Hereditary Motor and Sensory Neuropathy"
Laboratory research
21 |
15% |
Other research | 16 | 11% |
Disease patterns and progression | 16 | 11% |
Testing and diagnosis research | 8 | 6% |
Patient case studies | 8 | 6% |
Clinical study results | 7 | 5% |
New treatment approaches | 5 | 4% |
Meyers AL (2026). [PMID: 32491606](https://pubmed.ncbi.nlm.nih.gov/32491606/). *Unknown Journal*. [Other]
Thiriveedi M (2026). [PMID: 29939644](https://pubmed.ncbi.nlm.nih.gov/29939644/). *Unknown Journal*. [Other]
Zabaglo M (2026). [PMID: 32809368](https://pubmed.ncbi.nlm.nih.gov/32809368/). *Unknown Journal*. [Other]
Sutton AE (2026). [PMID: 29763013](https://pubmed.ncbi.nlm.nih.gov/29763013/). *Unknown Journal*. [Other]
Penmetsa GK (2026). [PMID: 32644436](https://pubmed.ncbi.nlm.nih.gov/32644436/). *Unknown Journal*. [Basic Science / Preclinical]
Shah SS (2026). [PMID: 34662020](https://pubmed.ncbi.nlm.nih.gov/34662020/). *Unknown Journal*. [Other]
Hoekstra M (2026). [PMID: 42139367](https://pubmed.ncbi.nlm.nih.gov/42139367/). *PLoS Negl Trop Dis*. [Review / Meta-Analysis]
Popowicz P (2026). [PMID: 30480960](https://pubmed.ncbi.nlm.nih.gov/30480960/). *Unknown Journal*. [Other]
Adeyinka A (2026). [PMID: 30020594](https://pubmed.ncbi.nlm.nih.gov/30020594/). *Unknown Journal*. [Other]
Adigun R (2026). [PMID: 28613625](https://pubmed.ncbi.nlm.nih.gov/28613625/). *Unknown Journal*. [Other]